FusionPharm Completes $1million Funding

Denver, Colorado, Feb. 25, 2014 (GLOBE NEWSWIRE) -- FusionPharm, Inc. (OTC: FSPM), manufacturer of the PharmPod™ (www.pharmpods.com) professional cultivation system, is pleased to announce that it has completed a $1million round of equity funding. Management intends to use the funds to complete outfitting of its recently expanded manufacturing facilities, provide for construction of new sales centers in key markets and to provide operations funding for acquisition of key personnel.

About FusionPharm Inc. (FSPM)

FusionPharm, Inc. (FSPM) (www.fusionpharminc.com) was organized to capitalize on opportunities present in the rapidly growing vertical farming and cannabis industries. FusionPharm's primary focus is the development and deployment of the patent pending PharmPods™ advanced hydroponic commercial cultivation systems. PharmPods are constructed from standard ISO steel shipping containers that are repurposed for use in indoor controlled environment agriculture. Modular, stackable, cost competitive and financeable, PharmPods have become the industry leader for professional, commercial scale indoor plant cultivation

Cautionary Language Concerning Forward-Looking Statements

This release contains "forward-looking statements" that include information relating to future events and future financial and operating performance. The words "may," "would," "will," "expect," "estimate," "can," "believe," "potential" and similar expressions and variations thereof are intended to identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results. Forward-looking statements are based on information available at the time they are made and/or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. No information in this press release should be construed as an indication of the Company's future financial performance, revenues or stock price. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

info@fusionpharminc.com

www.fusionpharminc.com

www.pharmpods.com

CONTACT: FusionPharm, Inc. (720) 458-0686 info@fusionpharminc.com Source:FusionPharm, Inc.